Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LenVitol is a dietary supplement developed and manufactured by Oleofarm, consisting of high-quality, cold-pressed flaxseed oil (olej lniany). It is characterized by a high concentration of polyunsaturated fatty acids, specifically alpha-linolenic acid (ALA, an omega-3) and linoleic acid (LA, an omega-6). ALA is an essential fatty acid that the human body cannot synthesize, and its consumption is associated with the maintenance of normal blood cholesterol levels when unsaturated fats replace saturated fats in the diet. LenVitol is marketed for general cardiovascular support and nutritional supplementation, and it is frequently utilized as a component of the Dr. Budwig diet protocol. The product is produced from selected high-linolenic flax seeds using traditional cold-pressing methods to ensure the preservation of its natural bioactive components and nutritional integrity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LenVitol.